Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 OCF Margin % is -21.82% as of Sep. 2025. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 961 Drug Manufacturers companies, Sai Parenteral's ranks worse than 87.3% on this metric.
The historical rank and industry rank for Sai Parenteral's's OCF Margin % or its related term are showing as below:
NSE:SAIPARENT'
s OCF Margin % Range Over the Past 10 Years
Min: -19.36 Med: -13.22 Max: 6.7
Current: -21.82
During the past 3 years, the highest OCF Margin % of Sai Parenteral's was 6.70%. The lowest was -19.36%. And the median was -13.22%.
NSE:SAIPARENT's OCF Margin % is ranked worse than 87.3% of 961
companies
in the Drug Manufacturers industry
Industry Median: 9.92
vs NSE:SAIPARENT: -21.82
The historical data trend for Sai Parenteral's's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's OCF Margin % Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
OCF Margin %
-13.22
-19.36
6.70
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
OCF Margin %
0.00
0.00
0.00
-21.82
NSE:SAIPARENT vs LLY, JNJ, ABBV: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's (NSE:SAIPARENT) has a OCF Margin % of -21.82% as of Sep. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sai Parenteral's and its competitors. According to the industry distribution chart, Sai Parenteral's ranks #839 out of 961 companies in the Drug Manufacturers industry, placing it in the top 87.3%.
Is Sai Parenteral's' OCF Margin % too high?
Sai Parenteral's' current OCF Margin % is -21.82%. Based on the distribution chart, Sai Parenteral's ranks #839 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' OCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #839 out of 961 companies for OCF Margin %. This places Sai Parenteral's in the lower half of its industry. The industry median OCF Margin % is 9.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.92, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current OCF Margin % is -21.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current OCF Margin % of -21.82%. The current OCF Margin % is -21.82%. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current OCF Margin % is -21.82% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
